SAM
VKTX icon

S.A. Mason’s Viking Therapeutics VKTX Stock Holding History

S.A. Mason’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
+2,900
New +$93.7K 0.03% 269
2026
Q1 		– Sell
-2,900
Closed -$102K – 277
2025
Q4 		$102K Buy
+2,900
New +$103K 0.04% 259
2025
Q3 		– Sell
-1,800
Closed -$47.7K – 357
2025
Q2 		$47.7K Hold
1,800
– – 0.02% 289
2025
Q1 		$43.5K Hold
1,800
– – 0.02% 281
2024
Q4 		$72.4K Buy
1,800
+300
+20% +$17.1K 0.04% 251
2024
Q3 		$95K Sell
1,500
-100
-6% -$5.87K 0.05% 232
2024
Q2 		$84.8K Buy
+1,600
New +$105K 0.05% 226

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

S.A. Mason's VKTX Position: Q2 2026 in Review

S.A. Mason opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 2,900 shares worth $113K. The stake represents 0.03% of the portfolio and ranks #269 among its holdings. This is a return to the name: S.A. Mason previously reported a position in VKTX as recently as Q4 2025.

S.A. Mason first reported a position in VKTX in Q2 2024 and has held it in 7 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • S.A. Mason held 2,900 shares of Viking Therapeutics worth $113K as of Q2 2026.
  • Viking Therapeutics was a new S.A. Mason position in Q2 2026.
  • Viking Therapeutics made up 0.03% of S.A. Mason's portfolio in Q2 2026, its #269 holding.
  • S.A. Mason first reported a position in Viking Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on S.A. Mason's 13F filing for Q2 2026, filed 31 Jul 2026.